Table 1 Comparison of MultiCoV-Ab and commercial IVD tests in screening results and manufacturer specifications as stated in the assay manuals.
Manufacturer specification | Correctly classified | Found | Found | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Antigen | >14 days post infection | Infected | Uninfected | sensitivity | specificity | PPV at 3% | NPV at 3% | |||
Assay | Detection | used | Sensitivity | Specificity | (of 205) | (of 72) | (95% CI) | (95% CI) | Prevalence | Prevalence |
MultiCoV-Ab | IgG | S Trimer + RBD | — | — | 181 | 72 | 88.3% (83.1–92.4%) | 100% (95.0–100%) | 100% | 99.6% |
Roche | Total Ig | N | 100% n = 29 | 99.8% n = 5272 | 173 | 72 | 84.4% (78.7–89.1%) | 100% (95.0–100%) | 100% | 99.5% |
Siemens | Total Ig | S1 RBD | 100% n = 47 | 99.8% n = 1589 | 170 | 72 | 82.9% (77.1–87.8%) | 100% (95.0–100%) | 100% | 99.5% |
Euroimmun | IgG | S1 | 100% n = 13 | 99.0% n = 1261 | 164 | 70 | 80.0% (73.9–85.2%) | 97.2% (90.3–99.7%) | 46.9% | 99.4% |
MultiCoV-Ab | IgA | S Trimer + RBD | — | — | 158 | 72 | 77.1% (70.7–82.6%) | 100% (95.0–100%) | 100% | 99.3% |
Euroimmun | IgA | S1 | 100% n = 13 | 90.4% n = 1261 | 157 | 62 | 76.6% (70.2–82.2%) | 86.1% (75.9–93.1%) | 14.6% | 99.2% |
